



A 42 years old man with HIV-Ab positive, candidate for heart transplant

Dr Monireh Kamali
Rajai cardiovascular institute
2025



- Educated petroleum engineer with ischemic cardiomyopathy
- Evaluated and listed for heart transplant.
- Serologic testing for HIV, hepatitis B and C was negative, while CMV and EBV IgG were positive.
- No absolute or relative contraindications to transplantation were identified.





- Vaccination was done:
- Influenza
- Pneumococcal 13
- Hepatitis b
- DT





- Wait in list for 1 month
- After 1 month, he returned with decompensated heart failure. The only choice for treatment and cure on that time was transplant. (LVAD not available)
- Per hospital protocol, viral markers were rechecked.
- HIV screening revealed reactive 4th generation HIV 1/2 antigen/antibody assays.
- He denied prior blood transfusions, intravenous drug use, or other recognized risk factors for HIV infection.



- HIV screening revealed repeatedly (in our hospital and another referral lab) to rule out false positive result. one sample was positive again.
- the HIV-1 RNA nucleic acid test (NAT) was undetectable (<20 copies/mL), and the CD4 count was 1865 cells/mm.
- None of our surgeons accepted to operate him.



- He received conservative treatment and renal failure happened.
- After that his family try to take allocation for heart transplant and finally another hospital accepted to do transplantation as a non-HIV positive patient.



- We did not have any news from him until he came back after 2 months post transplantation. He was in good condition.
- The subsequent course remained uneventful until 4 months after the transplant, when the patient developed persistent leukopenia.
- Initially, the dose of mycophenolate mofetil was reduced. However, when leukopenia persisted (WBC count = $2.8 \times 10^3/\mu\text{L}$ with 59% neutrophils, 2% bands, 34% lymphocytes, 2% monocytes, 2% eosinophils and 1% basophils), HIV serology was ordered and the ELISA test was again positive. At that time, the viral load by PCR was 210 751 copies/mL and the CD4 cell count was 335 cells/mm³.



Positive test result: an unexpected finding
I don't have any idea!



Management of Antiretroviral Therapy (ART) Post- Transplant and Drug-Drug Interactions (DDI)

- ART Initiation: ART is ideally initiated pre-transplant with viral suppression. Post-transplant initiation requires careful synchronization with immunosuppression dosing to maintain viral control while preventing rejection.
- DDI Management: The primary challenge involves interactions between ART (especially PIs/Boosters utilizing CYP3A4) and Calcineurin Inhibitors (CNIs) like Tacrolimus.
- Mechanism: Certain ART components can drastically increase or decrease CNI levels, leading to toxicity or acute rejection, respectively.
- Resolution: Management relies on selecting ART regimens with minimal CYP3A4 liability (e.g., NRTIs, certain NNRTIs), and rigorous Therapeutic Drug Monitoring (TDM) to adjust CNI doses proactively.



- The patient developed acute allograft rejection shortly after the initiation of the combined antiretroviral and immunosuppressive regimens.
- This necessitated an immediate escalation of immunosuppressive therapy, specifically high-dose pulse corticosteroids, managed concurrently with ART adjustments under strict Therapeutic Drug Monitoring (TDM) to mitigate toxicity risk.
- Despite intensive, multi-agent immunosuppressive escalation aimed at reversing the acute rejection episode, the patient experienced refractory graft failure, leading to subsequent mortality.



THANK YOU

